Map of Pancreatica Walks and Runs

Category Archives: Pancreatic Cancer Clinical Trials

FOLFIRINOX (Minus Irinotecan) for Gemcitabine-refractory Disease

Since the promising article on the 4-drug 5-FU led FOLFIRINOX regimen for metastatic pancreatic cancer per the May 12, 2011 article in the New England Journal of Medicine, this treatment approach has emerged as a solid first-line option.  In the ensuing months there have been a number of studies exploring further options with this drug […]

Share Button

Clinical Trial with Votrient for Advanced NETs

Votrient (pazopanib) is a drug-agent of GlaxoSmithKline that appears to work through targeting angiogenesis and growth pathways, and has been approved for use in renal cell carcinoma and advanced soft tissue sarcoma. Two other recent targeted agents that have been approved by the U.S. FDA for the treatment of neuroendocrine tumors are everolimus and sunitinib. […]

Share Button

A Set-back for ARBs for the Treatment of Pancreatic Cancer?

Again, for more than a decade there have been theoretical discussions about the use of drugs commonly used to treat high blood pressure for use in the treatment of cancer – pancreatic cancer. And having just published a Pancreatica blog entry based on the pre-clinical study and work by Jain and colleagues from Harvard on […]

Share Button
Page 3 of 41234